An interplay between the diet and the microbiota appears to regulate the host responses. It is now well acknowledged that the microbiota and their metabolites such as short chain fatty acids, bile acids, etc modulates the metabolic status, educates the host’s intestinal immune system, and protects the host against invading pathogens and injury. Concomitantly, environmental factors such as diets and dietary components play a major role in shaping the microbiota, thereby modulating the host immune and epithelial responses, and ultimately directing the individual’s health status. Disruption in any of these elements or their interactions have been linked to the development and progression of a wide range of conditions including Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colorectal cancer, obesity, Parkinson’s disease, autism, asthma etc. While westernised diets (rich in fat/sugar and low in fibres) and dietary additives (e.g. emulsifiers) have been identified as risk factors for these disorders, other diets such as Mediterranean, Ketogenic and probiotics and prebiotics can serve as treatment strategies due to their impact on the microbiota and possibly the host.
This Research Topic welcomes Original Research, Reviews, Technology & Code and Perspective articles that provide new insights in intestinal health and disease, with a particular focus on:
1) Mechanisms regulated by food, food components, commensal vs pathogenic bacteria, and bacterial metabolites on immune and epithelial responses in the gut such as T cell response, antigen presentation, barrier function, cell death etc.
2) New in vitro and in vivo models and omics technologies to investigate food-microbiota, food-host, microbiota-host, bacterial metabolite-host, and food-microbiota-host interactions
3) New treatment strategies derived from new diets, dietary components, bacteria strains, or bacterial metabolites for the treatment of intestinal disorders.
Important note: Topic Editor Robert JM Brummer is a member of the Scientific Advisory Board of Chr Hansen A/S in Denmark and of the SAB of Amansia Biotech. The other Topic Editors declare no competing interests.
An interplay between the diet and the microbiota appears to regulate the host responses. It is now well acknowledged that the microbiota and their metabolites such as short chain fatty acids, bile acids, etc modulates the metabolic status, educates the host’s intestinal immune system, and protects the host against invading pathogens and injury. Concomitantly, environmental factors such as diets and dietary components play a major role in shaping the microbiota, thereby modulating the host immune and epithelial responses, and ultimately directing the individual’s health status. Disruption in any of these elements or their interactions have been linked to the development and progression of a wide range of conditions including Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colorectal cancer, obesity, Parkinson’s disease, autism, asthma etc. While westernised diets (rich in fat/sugar and low in fibres) and dietary additives (e.g. emulsifiers) have been identified as risk factors for these disorders, other diets such as Mediterranean, Ketogenic and probiotics and prebiotics can serve as treatment strategies due to their impact on the microbiota and possibly the host.
This Research Topic welcomes Original Research, Reviews, Technology & Code and Perspective articles that provide new insights in intestinal health and disease, with a particular focus on:
1) Mechanisms regulated by food, food components, commensal vs pathogenic bacteria, and bacterial metabolites on immune and epithelial responses in the gut such as T cell response, antigen presentation, barrier function, cell death etc.
2) New in vitro and in vivo models and omics technologies to investigate food-microbiota, food-host, microbiota-host, bacterial metabolite-host, and food-microbiota-host interactions
3) New treatment strategies derived from new diets, dietary components, bacteria strains, or bacterial metabolites for the treatment of intestinal disorders.
Important note: Topic Editor Robert JM Brummer is a member of the Scientific Advisory Board of Chr Hansen A/S in Denmark and of the SAB of Amansia Biotech. The other Topic Editors declare no competing interests.
